Australian real world clinical experience of ibrutinib (Imbruvica) in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) shows that patient duration on therapy matches closely with the phase 3 trial findings. Results from more than 1000 patients who accessed ibrutinib via the Named Patient Program (NPP) between 2014 and 2017 before it was listed on ...
Australian clinical experience shows time on treatment for ibrutinib
By Michael Woodhead
5 Jul 2018